Highlights on adjuvant alectinib in early ALK positive NSCLC: The ALINA study European Society for Medical Oncology (ESMO) 2:51 10 months ago 1 998 Скачать Далее
Adjuvant Alectinib vs. Chemotherapy in Early-Stage ALK+ NSCLC: Dr. Amit Kumar's Analysis | CRSF CRSF - Cancer Research and Statistic Foundation 7:32 2 months ago 2 Скачать Далее
NAUTIKA1: safety and tolerability of neoadjuvant alectinib in ALK-positive NSCLC VJOncology 0:56 2 years ago 483 Скачать Далее
ESMO 2023 Lung Cancer Highlights – Keynote 671 | ALINA | TropionLung01 | Oncology Brothers OncBrothers: Practice-Changing Cancer Discussions 18:24 9 months ago 3 556 Скачать Далее
The Alina Trial for ALK+ NSCLC GRACE - Global Resource for Advancing Cancer Education 1:13 10 months ago 110 Скачать Далее
Alectinib for the treatment of NSCLC: an update on the ALINA trial VJOncology 2:37 7 months ago 184 Скачать Далее
AACR 2023 highlights on advances in the neoadjuvant treatment of resectable NSCLC with John Heymach European Society for Medical Oncology (ESMO) 3:44 1 year ago 1 765 Скачать Далее
ASCO 2023 Highlights on adjuvant osimertinib in resected EGFR mutated NSCLC: The ADAURA trial European Society for Medical Oncology (ESMO) 6:20 1 year ago 3 161 Скачать Далее
The Alina Trial for ALK+ NSCLC - Targeted Therapies in Lung Cancer 2023 GRACE - Global Resource for Advancing Cancer Education 0:54 1 year ago 97 Скачать Далее
Dr. Velcheti on Potential of Alectinib in Frontline ALK-Positive NSCLC OncLive 1:42 7 years ago 223 Скачать Далее
Promising Phase III Results for Alecensa in Early-Stage ALK-Positive Lung Cancer Pharma News & Analysis 1:50 11 months ago 253 Скачать Далее
ASCO 2021 - Highlights on shifting PARPi to Early Breast Cancer: The OlympiA study European Society for Medical Oncology (ESMO) 6:16 3 years ago 1 853 Скачать Далее
Alectinib eclipses crizotnib for ALK positive lung cancer ecancer 4:00 7 years ago 1 720 Скачать Далее
Lung Summary post ESMO 2023 | Oncology Brothers | #2023 #cancer #esmo OncBrothers: Practice-Changing Cancer Discussions 0:58 9 months ago 128 Скачать Далее
Updated Data from Phase 2 Study of Alectinib in ALK–Positive Non–Small–Cell Lung Cancer VJOncology 2:00 7 years ago 318 Скачать Далее
Highlights on selpercatinib in RET fusion-positive NSCLC: The LIBRETTO-431 study European Society for Medical Oncology (ESMO) 3:58 10 months ago 1 105 Скачать Далее
Is there still a need of chemotherapy? | Oncology Brothers | #2023 #cancer #esmo OncBrothers: Practice-Changing Cancer Discussions 0:59 9 months ago 179 Скачать Далее
Neoadjuvant versus PeriOp Immunotherapy in NSCLC | Oncology Brothers | #2023 #cancer #esmo OncBrothers: Practice-Changing Cancer Discussions 0:57 9 months ago 140 Скачать Далее
2023 Best of Lung: Targeted Therapies in Lung Cancer Total Health | Oncology 30:32 10 months ago 12 830 Скачать Далее
